Remyelination

Remyelination is not a molecule or receptor but a *biological process* involving the regeneration of myelin sheaths around axons following damage in the central nervous system. This process is primarily mediated by oligodendrocyte precursor cells (OPCs), which proliferate, migrate into lesions, and differentiate into mature oligodendrocytes that form new myelin. Remyelinated axons typically have thinner sheaths than those formed during development but regain significant functional capacity and protection against degeneration. The efficiency of this repair mechanism declines with age and disease progression—especially notable in multiple sclerosis—making enhancement of remyelination an important therapeutic goal. Current drug development efforts focus on modulating cellular pathways that regulate OPC behavior rather than targeting "remyelination" as a discrete molecular entity[1][2][4][7].

Promotion of oligodendrocyte precursor cell (OPC) proliferation, migration, and differentiation into mature oligodendrocytes[1][2][4]. Modulation of signaling pathways such as Notch, purinergic receptors (P2Y2, P2Y12), and growth factors like PDGF and FGF[1][2][3].